Just a moment, the page is loading...

GSK-114700




Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 vaccine when administered according to alternative 2-dose schedules in 9 - 14 year old females
Human Papillomavirus Types 16 and 18 Vaccine
114700
NCT01381575 2011-000757-22
Infections, Papillomavirus
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided.
November 2016